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Summary
This article is a report of the fourth meeting of the Harmonising Outcome Mea-
sures for Eczema (HOME) initiative held in Malm€o, Sweden on 23–24 April
2015 (HOME IV). The aim of the meeting was to achieve consensus over the
preferred outcome instruments for measuring patient-reported symptoms and
quality of life for the HOME core outcome set for atopic eczema (AE). Following
presentations, which included data from systematic reviews, consensus discus-
sions were held in a mixture of whole group and small group discussions. Small
groups were allocated a priori to ensure representation of different stakeholders
and countries. Decisions were voted on using electronic keypads. For the patient-
reported symptoms, the group agreed by vote that itch, sleep loss, dryness, red-
ness/inflamed skin and irritated skin were all considered essential aspects of AE
symptoms. Many instruments for capturing patient-reported symptoms were dis-
cussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-
Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity
Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham
Eczema Severity Score] and, by consensus, POEM was selected as the preferred
instrument to measure patient-reported symptoms. Further work is needed to
determine the reliability and measurement error of POEM. Further work is also
required to establish the importance of pain/soreness and the importance of col-
lecting information regarding the intensity of symptoms in addition to their fre-
quency. Much of the discussion on quality of life concerned the Dermatology
Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, con-
sensus on a preferred instrument for measuring this domain could not be
reached. In summary, POEM is recommended as the HOME core outcome instru-
ment for measuring AE symptoms.
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What’s already known about this topic?
• Previous meetings of the Harmonising Outcome Measures for Eczema (HOME) ini-
tiative have achieved international consensus that the domains of clinician-reported
signs, patient-reported symptoms, quality of life and long-term control should be
measured as the core outcomes for atopic eczema clinical trials.
• It has been recommended that clinician-reported signs should be measured using
the Eczema Area and Severity Index.
What does this study add?
• During the HOME IV meeting (Spring 2015, Malm€o, Sweden), a consensus was
achieved that the Patient-Oriented Eczema Measure should be used to capture
patient-reported symptoms in future atopic eczema trials.
• The remaining two core outcome domains of quality of life and long-term control
require further work to determine the preferred core outcome measurement instru-
ments.
This is a report of the fourth meeting of the Harmonising
Outcome Measures for Eczema (HOME) initiative (HOME IV),
an initiative to validate and standardize the use of core out-
come measurement instruments for atopic eczema (AE) (also
known as atopic dermatitis). The main meeting was held in
Malm€o, Sweden on 23–24 April 2015 with a patient session
held prior to the main meeting on the afternoon of the 22
April. The full minutes including details of the discussions
and voting results from this meeting can be found at
http://nottingham.ac.uk/homeforeczema/meetings-and-events/
home-iv-meeting-2015.aspx.
The aims of the HOME IV meeting were:
1 To discuss systematic review data on the measurement
properties of instruments available for measuring patient-
reported symptoms and quality of life (QoL) in AE trials.
2 To work towards a consensus on which instruments should
be recommended for inclusion in the core outcome set for
patient-reported symptoms and QoL.
3 To determine how best to proceed with the core outcome
domain long-term control.
A summary timeline of progress with the HOME core out-
come set development process is shown in Table 1. Full
details of outputs from previous HOME meetings can be
found at http://nottingham.ac.uk/homeforeczema/meetings-
and-events/next-home-meeting.aspx/.
An invitation to participate in the meeting was sent to all
246 HOME members. Membership of the HOME initiative is
open to anyone with an interest in outcome measures for AE.
There were a total of 70 participants at the HOME IV meeting
from North and South America, Europe, Asia and Australia
(Fig. 1). Delegates included patients with AE or patient repre-
sentatives, clinicians, methodologists and representatives of the
pharmaceutical industry (Fig. 2).
Methods
All patients and patient representatives were invited to attend
a premeeting session on the afternoon prior to the meeting
where the background to the HOME initiative and relevant
terminology was explained to enable them to participate fully
in the subsequent meetings over the following 2 days.
The HOME meeting structure included a combination of
presentations of background information and data from mem-
bers of the HOME research groups, and nominal group tech-
niques to achieve consensus.1 For each topic there were large
group discussions and small breakout group discussions where
participants were allocated a priori to a group to ensure repre-
sentation from the different stakeholder groups and countries.
Voting was conducted anonymously using electronic handsets
[Interactive Voting System, IVS and RF2 Keypads, Dronten,
the Netherlands (https://www.ivsystem.nl/en/)] coordinated
by Teletech Konference Kommunikation (Herlev, Denmark)
(http://www.teletech.dk). The results were presented to the
group once the voting had closed. Only members who were
present for the discussions were permitted to vote and all
stakeholder groups participated in the voting. The voting rule
agreed at HOME II was used at this meeting, i.e. consensus is
reached where less than 30% of voters disagree.2
Results
Session 1: Introduction
Presentation 11: Introduction and background
Professor Hywel Williams opened the meeting by describing
the many outcome measures for AE currently being used and
why this hampers evidence-based practice. He also
© 2016 The Authors. British Journal of Dermatology
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summarized the progress made by the HOME initiative to
date.2–4 He encouraged the group to put aside prejudices and
allegiances to achieve the greater good for patient care. He
concluded by reminding the group of the previously agreed
consensus voting rules.2
Presentation 12: Reflections from Outcome Measures in
Rheumatology (OMERACT)
Dr Jas Singh, attending as an independent advisor from the
Outcome Measures in Rheumatology (OMERACT) group
(http://www.omeract.org), acted as a group moderator. Dr
Singh stated that the purpose of this meeting was to agree on
core outcome measurement instruments and emphasized that
the patient voice is crucial in determining the patient-reported
outcome measures of symptoms and QoL. He encouraged the
group to listen to disagreement and to share their views during
the meeting rather than afterwards. Dr Singh reminded partici-
pants that there is never a perfect instrument and developing a
new instrument takes years of work. He urged everyone to
ask themselves the question ‘Can I live with it?’ rather than ‘Is
this the perfect solution?’.
Table 1 Timeline for Harmonising Outcome Measures for Eczema (HOME) development of a core outcome set for atopic eczema (AE)
HOME meeting Key output from the meeting
Work undertaken to inform next meeting (by working
groups)
HOME I Munich, Germany
(July 2010)
• Confirmed international enthusiasm for
establishing a core outcome set for eczema
• International e-Delphi consensus study to inform
choice of core outcome domains for trials and
clinical practice10
• Link with key groups to inform methodology
(OMERACT, COMET, COSMIN)11,12
• Systematic review of outcome instruments used in
eczema trials12
• Validation of AE signs scales13
HOME II Amsterdam, the
Netherlands (April 2011)
• Agreed to focus initially on core outcome
set for clinical trials
• Confirmed core outcome domains for
clinical trials:
1 Signs
2 Symptoms
3 Quality of life
4 Long-term control
• HOME Roadmap methodology developed5
• Systematic review of validation studies for
instruments to measure AE signs11
HOME III San Diego, CA,
U.S.A. (April 2013)
• Agreed core instrument for clinician-
reported signs is Eczema Area Severity
Index (EASI)3
• Systematic review of how symptoms are captured
in clinical trials14
• Systematic review of validation studies for
instruments to measure AE symptoms15
• Systematic review of how quality of life is captured
in clinical trials16
• Systematic review of validation studies for
instruments to asses quality of life in patients with
AE (adults)9
• Systematic review of how long-term control is
captured in trials17
• International patient survey18
HOME IV Malm€o, Sweden
(April 2015)
• Agreed core instrument for patient-reported
symptoms is Patient-Oriented Eczema
Measure (POEM)19
• Surveys, qualitative studies and e-Delphi consensus
study to establish what patients and healthcare
professionals mean by long-term control
• Validation studies of different methods of
capturing long-term control
HOME V (To be confirmed,
2017)
• Aim to agree core instrument for quality
of life (adults) and long-term control
COMET, Core Outcome Measures in Effectiveness Trials; COSMIN, COnsensus-based Standards for the selection of health Measurement
INstruments; OMERACT, Outcome Measures in Rheumatology.
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Session 2: Symptoms domain (Chair: Eric Simpson and
Phyllis Spuls)
Presentation 21. Introduction
Professor Phyllis Spuls opened the symptoms session stating that
the goal was to agree on a core outcome instrument to measure
the symptoms of AE in clinical trials and explained how the sys-
tematic reviews conducted by the symptoms working group
related to the HOME roadmap.5 The group agreed by vote that
a patient-reported symptom should be defined as ‘departure
from normal function, appearance or feeling that is noticed by
the patient, indicating the presence of disease or abnormality’
(95% agreed, 3% disagreed, 2% unsure).
Professor Spuls then described the individual symptoms that
had been identified as being important to measure. These
were identified from a global survey of patients (Presentation
22), input from patients at the HOME IV meeting and a sys-
tematic review of what symptoms are measured and reported
in clinical trials (Presentation 23).
Presentation 22. Atopic eczema symptoms: what is
important to patients?
Dr Laura von Kobyletzki presented the results of a global
patient survey in which respondents were given a list of AE
symptoms and asked to give each a rating on a 5-point Lik-
ert scale ranging from ‘very important’ to ‘not relevant to
me’ in response to the question ‘How important are these
features in deciding whether or not a treatment is work-
ing?’.
A total of 1104 responses were received from 35
countries, mainly in Europe and North America. A wide
range of severity and skin colours were represented. Nine
items were rated as being quite or very important by more
than 80% of the respondents. These included itch, pain/
soreness, skin feels hot or inflamed, bleeding, involvement
of visible or sensitive body sites, cracks, sleep difficulties,
amount of body affected and weeping. Itch and pain/
soreness were the symptoms most frequently rated as very
or quite important.
Presentation 23. A systematic review of how symptoms
are reported in randomized controlled trials of atopic
eczema treatments
Dr Louise Gerbens presented data from a systematic review
revealing that most of the clinical trials of treatments for AE
reported symptoms (78%), with itch and sleep loss being the
most commonly reported symptoms (98% and 61%, respec-
tively). Symptoms were often reported as part of a composite
instrument and the most commonly used instrument to mea-
sure symptoms was the SCOring Atopic Dermatitis (SCORAD)
index (49%). However, most trials did not report the symp-
tom score separately, meaning that the treatment effect on
symptoms alone was not clear.
Whole group discussion
Patients gave feedback and reflections to the whole group on
their opinion regarding the most important symptoms and
why they felt that way. It became clear that many symptoms
may be related (e.g. sleep loss and soreness may be a direct
reflection of the degree of itch being experienced). There was
divided opinion on whether pain/soreness was a true symp-
tom of AE or a consequence of other symptoms such as crack-
ing.
Presentation 24. The COSMIN checklist
Dr Cecilia A.C. (Sanna) Prinsen presented an overview of the
COnsensus-based Standards for the selection of health Mea-
surement INstruments (COSMIN) taxonomy and the COSMIN
checklist (http://www.cosmin.nl), a tool developed to evalu-
ate the methodological quality of validation studies on the
measurement properties of health measurement instruments
used by the HOME initiative.6,7 Further quality criteria to eval-
uate the quality of the measurement instruments (i.e. mea-
surement properties) were discussed.8 There was a discussion
about how each instrument is given a quality rating and why
COSMIN is used in core outcome instrument selection in
HOME.
North America (n = 10)
South America (n = 3)
Europe (n = 48)
Asia (n = 7)
Australia (n = 2)
Fig 1. Geographic location of Harmonising Outcome Measures for
Eczema IV meeting participants.
Patient/patient 
representative (n = 12)
Clinician (n = 38)
Methodologist (n = 7)
Pharmaceutical 
industry 
representative (n = 13)
Fig 2. Background of Harmonising Outcome Measures for Eczema IV
meeting participants.
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Presentation 25. Systematic review of the measurement
properties of instruments designed to capture atopic
eczema symptoms
Professor Phyllis Spuls presented the preliminary results of a
systematic review completed by the symptoms working group
of the measurement properties of instruments designed to
measure AE symptoms. Each instrument was rated according
to the methodological quality of the validation studies and the
quality of the measurement instrument, by using the COSMIN
checklist and the quality criteria, respectively. For each
reviewed instrument, a standardized recommendation was
made based on the quality of validation studies found
(Table 2). These ratings helped to prioritize which instru-
ments to focus on in further discussion. Based on the prelimi-
nary results of the systematic review, recommendations were
made and can be found in Table 3.
Whole group discussion
After whole group discussions, it was agreed that the list of
symptoms to be considered by the groups was a comprehen-
sive list that captured all of the important AE symptoms (77%
agreed, 3% disagreed, 20% unsure). Because of the high num-
ber of symptoms associated with AE and (with the exception
of itch) the huge variation between patients, it was accepted
that producing a definitive shortlist of essential symptoms
would not be possible. However, the group agreed by voting
that itch, sleep loss, dryness, redness/inflamed skin and irri-
tated skin were all considered essential. There was no consen-
sus as to whether pain/soreness should be considered an
essential item (31% agreed, 37% disagreed, 32% unsure), but
it was agreed by vote that more research was needed to
explore the importance of pain/soreness in the assessment of
AE.
Breakout group discussions were then held (for groups see
Appendix 1). Each group was asked to consider the following
in their discussions:
1 Which symptoms are considered ‘essential’ to be included
from the long list of all symptoms?
2 Which is the preferred measurement instrument(s) taking
into account the content (important symptoms) and the
validation of instruments?
Each group then presented the results of their discussions to
the whole group. All six groups reported that the preferred
Table 2 Definitions used for determining summary quality ratings
Rating Definition Recommendation
A Measurement instrument meets all required quality items Could be recommended for use
B Measurement instrument meets two or more required quality
items, but performance in all other required quality items is
unclear
Has the potential to be recommended in the future depending on
the results of further validation studies
C Measurement instrument has low quality in at least one
required quality criterion
Not recommended for use
D Measurement instrument has very little validation work so the
performance in all or most relevant quality items is unclear
Not recommended to be used until further validation has been
performed. Future recommendation would depend on the results
of further validation studies
Table 3 Rating of outcome instruments used to capture patient-reported symptoms
Rating Recommendation
A  Could be recommended for use
B ISS, POEM, SA-EASI Has the potential to be recommended in the future depending on the
results of further validation studies
C ADAM, EIQ, LIS, subjective SCORAD, ZRADSQ Not recommended for use
D ADQ, CoIQ, mEASI, method 4, NESS, PO-SCORAD, SDQ Not recommended to be used until further validation has been
performed. Future recommendation would depend on the results of
further validation studies
ADAM, Atopic Dermatitis Assessment Measure; ADQ, Atopic Dermatitis Quickscore; CoIQ, web-based Characteristics of Itch questionnaire;
EIQ, Eppendorf Itch Questionnaire; LIS, Leuven Itch Scale; mEASI, Modified Eczema Area and Severity Index; NESS, Nottingham Eczema
Severity Score; SCORAD, SCOring Atopic Dermatitis index; SDQ, Skin Detective Questionnaire; ZRADSQ, Zheng-Related Atopic Dermatitis
Symptom Questionnaire. Following small group and whole group discussions, it was agreed that only Patient-Oriented Eczema Measure
(POEM), Patient-Oriented SCOring Atopic Dermatitis index (PO-SCORAD) and Self-Administered Eczema Area and Severity Index (SA-EASI)
would be considered in the final vote (67% agreed, 25% disagreed, 8% unsure). Post meeting note: some instruments have subsequently
changed category due to updating of the systematic review of validation studies for these instruments.14
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instrument was Patient-Oriented Eczema Measure (POEM), but
other instruments were also discussed [Itch Severity Scale,
Self-Administered Eczema Area and Severity Index (SA-EASI),
Patient-Oriented SCOring Atopic Dermatitis index (PO-
SCORAD), Atopic Dermatitis Quickscore, Nottingham Eczema
Severity Score]. The meeting then broke for the day.
The following day began with the group voting on instru-
ments that had been determined by the groups as having
potential for inclusion in the core set, taking into account the
measurement properties and the list of essential symptoms. It
was agreed by vote that only POEM, SA-EASI and PO-SCORAD
were to be considered for the final vote (67% agreed, 25%
disagreed, 8% unsure). Prior to the final vote, anyone with a
conflict of interest associated with these instruments declared
themselves to the group, but all present at the meeting were
included in the voting.
The group voted on each of the three outcome instruments
separately to the question ‘Is [instrument name] an adequate
instrument to measure the domain of patient-reported symp-
toms?’ (Table 4).
Consensus was achieved that POEM is the preferred instru-
ment to measure patient-reported symptoms and that it should
be recommended as the HOME core outcome instrument for
symptoms.
Remaining validation gaps
Although POEM generally passes the OMERACT filter of truth,
discrimination and feasibility, it was agreed that the validation
gaps for POEM should be addressed in time as per the HOME
roadmap. Uncertainties remain around the structural validity
of the POEM scale and its cross-cultural validity. Reliability
and measurement error also remain unclear. The importance
of the intensity of symptoms (in addition to the frequency of
symptoms) requires further study.
The symptoms session was then brought to a close.
Session 3: Quality of life domain (Chair: Hywel Williams
and Jas Singh)
Presentation 31. Introduction
Dr Christian Apfelbacher opened the session by explaining the
difficulties in defining QoL and its multidimensionality. Many
instruments that have been developed are measures of func-
tional limitations. Modern instruments are now usually devel-
oped using conceptual models. The group discussed the
important role of patients in relation to this topic and
accepted that this would be challenging to determine the core
outcome measure for this domain.
Presentation 32. Systematic review of how quality of life
is measured in atopic eczema clinical trials
Daniel Heinl presented a scoping review showing that approx-
imately one in five clinical trials concerning AE report on QoL
and 22 different instruments had been used. Most were skin
specific with a few generic and AE-specific instruments.
The whole group discussion then focused on adults because
the required systematic review on validation of QoL scales for
children has not yet been completed. The patients and patient
representatives were asked about the aspects of AE that
affected their QoL. It was clear that having AE affected both
their personal and professional lives.
Presentation 33. Systematic review of measurement
properties of quality of life instruments in adults
Daniel Heinl summarized the methods used in this review of
the measurement properties of QoL instruments in adults and
emphasized that only validation or development studies were
included in the review, not indirect evidence such as respon-
siveness collected in trials. Each instrument had been given a
rating of A, B, C or D as per the symptoms review (Table 5).9
Whole group discussion
The following whole group discussion explained that different
language versions are treated separately because the measure-
ment properties relate to the data, rather than the instrument
itself, and therefore small nuances of interpretation in differ-
ent settings may influence the performance of the scale. Ide-
ally, validation studies should be performed in each language.
It was generally agreed that the number of questions in the
instrument is important for feasibility.
The meeting then split into the same smaller breakout
groups as for the symptoms session. Each group was asked to
consider what they felt were the essential domains for QoL
and to discuss their preferred QoL instruments.
Most groups felt that emotions, treatment burden and per-
sonal relationships were essential aspects of QoL. All groups
had concerns about some aspects of all currently available
instruments, such as acceptability to patients, structural valid-
ity, content validity and cross-cultural validity. Three of the
six groups preferred the Dermatology Life Quality Index
(DLQI), one group preferred Quality of Life Index for Atopic
Dermatitis (QoLIAD), and two felt unable to state a preferred
instrument based on the available evidence. Other instruments
that were rated B or C were also discussed within the groups
and comments were presented.
Table 4 Results of final voting to decide core outcome instrument
(%): Patient-Oriented Eczema Measure (POEM) confirmed as preferred
instrument
Agreed Disagreed Unsure
POEM 875 30 94
PO-SCORAD 154 615 231
SA-EASI 47 719 234
PO-SCORAD, Patient-Oriented SCOring Atopic Dermatitis index;
SA-EASI, Self-Administered Eczema Area and Severity Index.
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The whole group discussions that followed focused mainly
on the DLQI and QoLIAD, but other instruments including
Skindex were also discussed.
The group then voted that psychological functioning, social
functioning and physical functioning are all essential subdo-
mains for the construct QoL and that there are no other essen-
tial subdomains. Subsequent voting on whether the DLQI,
QoLIAD or Skindex could be recommended for the core out-
come set failed to reach a consensus approval for any of the
three scales (Table 6). As a result, no QoL instrument was rec-
ommended for the core outcome set at this meeting.
The reasons why DLQI was not rated more highly were dis-
cussed in detail, as DLQI is the most commonly used QoL
scale in dermatology trials.
The issues around the structural validity of DLQI, particu-
larly the redundancy of some items on the scale, lack of cul-
tural validity data and the problem of subquestions within a
single item were discussed. The group discussed what changes
and further validation studies would be required to enable
DLQI to be recommended for the core set and the possibility
of a conditional recommendation for DLQI was rejected. It
was confirmed that the main areas of concern are content
validity and structural validity. In addition, responsiveness has
not yet been established in patients with AE. The group also
determined that further testing of QoLIAD with respect to
measurement error, reliability, cross-cultural validity and
responsiveness was required to be able to recommend this
instrument and concerns were raised about the acceptability of
the scale to patients.
Discussion also covered the need for other factors to be
taken into account when selecting a QoL instrument, includ-
ing the need to compare AE with other skin conditions, the
need to compare new studies with older ones, the need for
good responsiveness of the instrument and the length of time
it takes to develop a new instrument.
The discussion showed a lot of support for DLQI, so the
group were asked to decide whether the DLQI should be
voted on again (as a preliminary recommendation), but there
was insufficient support for this as a way forward (38%
agreed, 48% disagreed, 14% unsure). Therefore, consensus on
a preferred instrument for QoL in adults was not reached. The
session on QoL was then brought to a close. A future research
agenda for the QoL working group will be established.
Session 4: Long-term control domain (Chair: Jochen
Schmitt)
Presentation 41: Introduction to the domain of long-term
control
Professor Kim Thomas opened the session by discussing what
is meant by the core outcome long-term control and
reminded the group that previous agreement had been
reached that the long-term control should apply to trials with
a duration of 3 months or longer.
Owing to time constraints, meeting participants were asked
to complete a questionnaire to elicit opinion for guiding
future work in preparation for the HOME V meeting in 2017.
Presentation 42: How has long-term control been
captured in randomized controlled trials of atopic eczema
treatments?
Dr Sebastien Barbarot presented a systematic review showing
that most long-term control studies use repeated measurement
of disease severity (usually monthly clinician-reported out-
comes assessing disease severity). Less than a third used either
Table 5 Rating of outcome instruments used to capture health-related
quality of life
Degree of
recommendation Instrument(s) Recommendation
A None Could be
recommended for
use
B English QoLIAD
(U.K.)
Has the potential to
be recommended in
the future depending
on the results of
further validation
studies
English QoLIAD
(U.S.A.)
French QoLIAD
German QoLIAD
Spanish QoLIAD
C English DLQI (U.K.) Not recommended for
useISDL
Dutch QoLIAD
D DIELH Not recommended to
be used until further
validation has been
performed. Future
recommendation
would depend on
the results of further
validation studies
Danish DLQI
German DLQI
Spanish DLQI
FLQA-c
FLQA-d
Italian QoLIAD
German Skindex-29
DIELH, German Instrument for the Assessment of Quality of Life
in Skin Diseases; DLQI, Dermatology Life Quality Index; FLQA,
Freiburg Life Quality Assessment; QoLIAD, Quality of Life Index
for Atopic Dermatitis; ISDL, The Impact of Chronic Skin Disease
on Daily Life; Post meeting note: some instruments have subse-
quently changed category as a result of updating of the system-
atic review of validation studies for these instruments (see
published review for details).9
Table 6 Results of final voting to decide core outcome instrument for
health-related quality of life (%): no consensus achieved
Agreed Disagreed Unsure
Dermatology life
quality index
45 35 20
Quality of life index for
atopic dermatitis
26 59 15
Skindex 2 95 3
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flare data or standard medication use to assess long-term
control.
Presentation 43: Thoughts on long-term control – Is long-
term control a separate domain or a function of the other
three domains?
Professor Andreas Wollenberg presented thoughts on why the
only measure of long-term control that can be considered a
truly separate outcome is flares. He proposed a flare definition
and proposed a new outcome instrument based on time to
first flare presented as a Kaplan–Meier plot.
A brief whole group discussion followed where the group
discussed the potential advantages and limitations of a distinct
measure of long-term control compared with repeated mea-
surement over time using existing core instruments [e.g.
Eczema Area and Severity Index (EASI) or POEM]. Different
measures of long-term control could include time to first flare,
behavioural changes in response to worsening disease and the
use of rescue medicine. The need for a core set to include an
outcome instrument for long-term control that would enable
treatments for secondary flare prevention to be measured was
reiterated.
The group then voted on whether long-term control should
be measured as a separate unique construct (e.g. flares) or
whether it should be captured using repeated measurement of
one or more of the other three core outcomes. No consensus
was reached. This issue needs further discussion at HOME V.
The long-term control session was then brought to a close.
Post meeting
The results of the questionnaires (n = 23) completed by the
group were assessed after the meeting and this resulted in the
identification of two pieces of work to be taken forward by
the long-term control working group: qualitative work to
establish what long-term control means to patients (with ref-
erence to the existing qualitative literature) and a consensus
study to agree what is meant by the domain of long-term
control to inform discussions at the HOME V meeting in
2017.
Meeting close
Participants were made aware of the work to disseminate the
outcome of the previous HOME meeting (HOME III) with pub-
lications, an EASI training manual, EASI video and EASI app
available on the HOME website (www.homeforeczema.org).
Professor Hywel Williams then thanked everyone for com-
ing and for their valued contributions to the meeting. He
reflected that much had been achieved in terms of recom-
mending a new core instrument for patient-reported symp-
toms, but much remains to be done in terms of developing or
further testing of instruments for QoL, and more conceptual
work is needed on long-term control. He then drew the meet-
ing to a close.
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Appendix
Harmonising Outcome Measures for Eczema (HOME) IV breakout groups
Name Stakeholder Group Country
Group 1
Hywel Williams (facilitator for quality of life discussion) Clinician – Dermatology U.K.
Dedee Murrell (facilitator for symptoms discussion owing to the
conflict of interest for Hywel Williams)
Clinician – Dermatology Australia
Valeria Aoki Clinician – Dermatology Brazil
Julie Block Patient/Carer/Patient Representative U.S.A.
Lykke Bjerglund Graff Pharmaceutical Industry Representative Denmark
Burchard Marquort Patient/Carer/Patient Representative Sweden
Kristine Nograles Pharmaceutical Industry Representative
Yukihiro Ohya Clinician – Paediatrician Japan
Jasvinder Singh Methodologist U.S.A.
Anne Sulzer Pharmaceutical Industry Representative France
Helle Vestby Talmo Patient/Carer/Patient Representative Norway
Elke Weisshaar Clinician – Dermatology Germany
Group 2
Christian Apfelbacher (facilitator) Methodologist Germany
Katrina Abuabara Clinician – Dermatology/Methodologist U.S.A.
Marius Ardeleanu Pharmaceutical Industry Representative U.S.A.
Tim Burton Patient/Carer/Patient Representative U.K.
Amanda Creswell-Melville Patient/Carer/Patient Representative Canada
Laurent Eckart Pharmaceutical Industry Representative France
Takeshi Nakahara Clinician – Dermatology Japan
Ibrahim Nasr Clinician – Dermatology
Marie-Louise Schuttelaar Clinician – Dermatology The Netherlands
Tracey Sach Methodologist (Health Economist) U.K.
Annika Volke Clinician – Dermatology Estonia
Carl-Fredrik Wahlgren Clinician – Dermatology Sweden
Stephan Weidinger Clinician – Dermatology/Molecular Epidemiology Germany
Group 3
Kim Thomas (facilitator) Methodologist U.K.
Maren Awici-Rasmussen Patient/Carer/Patient Representative Norway
Sebastien Barbarot Clinician – Dermatology France
Linda Beckman Other – Researcher Sweden
Anthony Bragg Pharmaceutical Industry Representative U.K.
Rosemary Humphreys Patient/Carer/Patient Representative U.K.
Yoko Kataoka Clinician – Dermatology Japan
(continued)
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Appendix (continued)
Name Stakeholder Group Country
Yael Leshem Clinician – Dermatology U.S.A.
Bronwyn Lund Pharmaceutical Industry Representative Denmark
Hiroyuki Murota Clinician – Dermatology Japan
Florent Torchet Patient/Carer/Patient Representative France
Laura von Kobyletzki Clinician – General practitioner Sweden
Andreas Wollenberg Clinician – Dermatology Germany
Group 4
Phyllis Spuls (facilitator) Clinician – Dermatology The Netherlands
Maj Dinesen Pharmaceutical Industry Representative Denmark
Aaron Drucker Clinician – Dermatology Canada
Andrew Finlay Clinician – Dermatology U.K.
Louise Gerbens Clinical – Other MD PhD Student – Dermatology The Netherlands
Daniel Heinl Student of Medicine Germany
Marie-Anne Massuel Pharmaceutical Industry Representative France
Stephanie Merhand Patient/Carer/Patient Representative France
Jevgenija Smirnova Clinician – Junior Doctor Sweden
Ake Svensson Clinician – Dermatology Sweden
Group 5
Eric Simpson (facilitator) Clinician – Dermatology U.S.A.
Carsten Flohr Clinician – Paediatric Dermatology U.K.
Henrique Akira Ishii Patient/Carer/Patient Representative Brazil
Teresa Løvold Berents Clinician – Dermatology Norway
Ian Osterloh Pharmaceutical Industry Representative U.K.
Cecilia (Sanna) Prinsen Clinical Epidemiologist, Methodologist The Netherlands
Lynn Purkins Pharmaceutical Industry Representative U.K.
Shoko Shindo Clinician – Dermatology Japan
Eli Synnøve Gjerde Patient/Carer/Patient Representative Norway
Roberto Takaoka Clinician – Dermatology Brazil
Cathy Zhao Clinician – Dermatology Australia
Jan Pander Pharmaceutical Industry Representative The Netherlands
Group 6
Jochen Schmitt (facilitator) Clinician – Dermatology Germany
Madhur Garg Pharmaceutical Industry Representative Denmark
Jon Hanifin Clinician – Dermatology U.S.A.
Hitoshi Mizutani Clinician – Dermatology Japan
Matthew Ridd Clinical – General Practitioner/Academic Researcher U.K.
Marie Tauber Clinician – Dermatology France
Willem Kouwenhoven Patient/Patient Representative The Netherlands
Kosuke Yamaga Clinician – Dermatology Japan
Kim Katrine Clemmensen Clinician – Dermatology Denmark
One delegate (J.C.) acted as facilitator for the groups and did not participate in the small group discussions.
© 2016 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2016)
Meeting report: HOME IV, Sweden, J.R. Chalmers et al. 11
